Market Intelligence, Transcription Factor Targeting Strategies, and High-Purity Reagents for ETV4 (PEA3) Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ETV4 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ETV4 (PEA3) Full-Length & DNA-Binding Domain Recombinant Protein High purity (>95%), Sequence Verified, GST-tagged for enhanced solubility. Endotoxin <1EU/ug. |
View ETV4 Products |
| Gene Delivery | ETV4 Promise-ORF / Lentivirus Full-length ORF with nuclear localization signal (NLS) preserved for stable cell line generation and ChIP assays. |
View ETV4 Products |
| Benchmark Ab | Anti-ETV4 (Recombinant positive control) High-specificity reagent for intracellular detection. |
View ETV4 Products |
| Validator | ETV4 siRNA Set (3 unique sequences) For knockdown specificity verification and loss-of-function validation. |
View ETV4 Products |
| Related Target | ETV1 (ER81) PEA3 subfamily redundancy screening; structural homology assessment. |
View ETV1 Products |
| Related Target | ERG (ETS-Related Gene) ETS family selectivity counter-screen; prostate cancer fusion gene partner. |
View ERG Products |
| Related Target | MYC Parallel oncogenic transcription factor for combination therapy studies. |
View MYC Products |
| Related Target | TMPRSS2 Crucial fusion partner in TMPRSS2-ETV4 driven prostate cancer. |
View TMPRSS2 Products |
| Related Target | FGFR1 Upstream receptor tyrosine kinase driving ETV4 overexpression. |
View FGFR1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| DNA-Binding Domain Insolubility | High-purity GST-ETV4 DBD fusion (>95%) with verified sequence for EMSA and SPR screening |
| PEA3 Family Redundancy (ETV1/ETV5) | Ortholog-specific protein panels available for selectivity profiling and off-target assessment |
| Nuclear Entry & Degradation (PROTAC) | Full-length ETV4 Lentivirus with functional NLS for cellular degradation assay development |
| False Positives in Binding Assays | Sequence-verified siRNA included for target-specificity confirmation in reporter assays |
| Lack of Controls | Sequence Verified Recombinant antibodies included for standardized western blot and IHC benchmarking |
Live ETV4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- View Active Clinical Trials
- Latest Inhibitor Research
- Latest Resistance Research
- Recent Patent Filings
Global Clinical Landscape & Future Outlook
ETV4 (also known as Pea3) represents a formidable challenge in drug discovery as a member of the "undruggable" transcription factor class. Overexpression drives metastatic progression in prostate, breast, and lung adenocarcinomas through MMP activation and EMT induction. The race for ETV4 therapeutics is intensifying, with major players shifting focus from traditional mAbs to small molecule degraders and genetic medicines. While no direct ETV4 inhibitors have reached clinical trials, the landscape is shifting toward targeted protein degradation (PROTACs) and DNA-binding disruption strategies. The next wave of R&D is targeting direct protein degradation (PROTACs/Molecular Glues) and specifically addressing ETV4 gene fusions in solid tumors. As first-generation degraders enter preclinical development, the demand for high-quality DNA-binding domain proteins and cellular overexpression models is intensifying.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PROTAC / Degrader | Academic Consortia, Emerging Biotech, Preclinical Innovators | Metastatic Prostate Cancer, Breast Cancer | Full-length ETV4 Cell Lines (Lentivirus) for degradation efficiency assessment; Ubiquitination Assay with high purity recombinant ETV4 |
| siRNA / ASO | Emerging Biotechs | Solid Tumors | Knockdown Validation (Need ETV4 Benchmark Abs) for RNA-based therapy development |
| DNA-Binding Inhibitors / Small Molecule | Early Discovery Programs, Academic / Biopharma | TNBC, Lung Adenocarcinoma, Gastric Cancer | Purified ETV4 DBD Protein (>95%) for EMSA, thermal shift assays, and protein-DNA binding assay (native conformation) |
| Indirect (MAPK pathway) | Novartis, Pfizer | Solid Tumors | ETV4 Reporter Assay Cell Lines for pathway inhibition validation |
| Molecular Glue | Preclinical Discovery | Oncology | Selectivity Panels (ETV4 vs ETV1 vs ERG) for specificity profiling |